Turn Therapeutics
TrialRedline tracks 1 clinical trial sponsored by Turn Therapeutics: 1 Phase 2 / 3.
Company identity has not yet been verified
Which trial dates moved later?
Turn Therapeutics clinical trials we track
Check company identity sourcePhase 2 / 3 1 trial
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)NCT07355075 | GX-03, Vehicle | Recruiting | 2027-01-20Estimated |
Drugs in these trials
Names as written in the registry records.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in Investigator Global Assessment (IGA) at Week 8. After: Measure: vIGA-AD Success at Week 4 Measure: EASI-75 at Week 4 Measure: EASI-90 at Week 8 Measure: EASI-100 at Week 8.
Planned enrollment increased by 80 participants
Before: 110 participants (planned). After: 190 participants (planned).
Primary completion date changed
Before: 10 Jul 2026. After: 20 Jan 2027.
Phase changed
Before: PHASE2. After: PHASE2, PHASE3.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in Eczema Area and Severity (EASI). After: Measure: Change in Investigator Global Assessment (IGA) at Week 8.
Planned enrollment increased by 10 participants
Before: 100 participants (planned). After: 110 participants (planned).
Primary completion date changed
Before: 31 May 2026. After: 10 Jul 2026.